Bridgewater-based Sanofi announced on Thursday the completion of its acquisition of Synthorx Inc. for $68 per share in cash.
“The acquisition of Synthorx perfectly aligns with our R&D strategy, enhancing our position as an emerging leader in the area of oncology and immunology,” said Sanofi Chief Executive Officer Paul Hudson. “We gain access to both great scientists and science with THOR-707, an engineered not-alpha IL-2 for the treatment of solid tumors which induces strong immunological responses in vivo, additional intriguing pre-clinical assets, and a powerful platform that complements our ongoing oncology and immunology research.”
The tender offer for all of the outstanding shares of Synthorx common stock expired as scheduled at one minute after 11:59 p.m. EST on Jan. 22, 2020. The minimum tender condition and all of the other conditions to the offer have been satisfied and on Jan. 23, 2020, Sanofi and its wholly owned subsidiary Thunder Acquisition Corp. (the purchaser), accepted for payment and will promptly pay for all shares validly tendered and not properly withdrawn.
Following its acceptance of the tendered shares, Sanofi completed its acquisition of Synthorx through the merger of Thunder Acquisition with and into Synthorx, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Synthorx continuing as the surviving corporation and becoming an indirect, wholly-owned subsidiary of Sanofi.